0001104659-23-127810.txt : 20231220
0001104659-23-127810.hdr.sgml : 20231220
20231220191618
ACCESSION NUMBER: 0001104659-23-127810
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231219
FILED AS OF DATE: 20231220
DATE AS OF CHANGE: 20231220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McKelligon Brian
CENTRAL INDEX KEY: 0001857447
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40344
FILM NUMBER: 231502519
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE
STREET 2: 6TH FLOOR
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akoya Biosciences, Inc.
CENTRAL INDEX KEY: 0001711933
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 475586242
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE
STREET 2: 6TH FLOOR
CITY: MARLBOROUGH
STATE: MA
ZIP: 01762
BUSINESS PHONE: 855.896.8401
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE
STREET 2: 6TH FLOOR
CITY: MARLBOROUGH
STATE: MA
ZIP: 01762
4
1
tm2333436-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-12-19
0
0001711933
Akoya Biosciences, Inc.
AKYA
0001857447
McKelligon Brian
100 CAMPUS DRIVE, 6TH FLOOR
MARLBOROUGH
MA
01752
1
1
0
0
President and CEO
1
Common Stock
2023-12-19
4
M
0
7500
0.303
A
160063
D
Common Stock
2023-12-19
4
S
0
7500
4.4754
D
152563
D
Employee Stock Option (Right to Buy)
0.303
2023-12-19
4
M
0
7500
0.00
D
2027-11-09
Common Stock
7500
305629
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated August 16, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.20 to $4.625, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one-fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on July 14, 2018, subject to reporting person's continuous employment
/s/ Brian McKelligon
2023-12-20